News for 'drug manufacturing'

Hetero's generic version of remdesivir to be sold @ Rs 5,400/vial

Hetero's generic version of remdesivir to be sold @ Rs 5,400/vial

Rediff.com24 Jun 2020

The company is set to deliver the first set of 20,000 vials in two equal lots of 10,000 each, one of which will be immediately supplied to Hyderabad, Delhi, Gujarat, Tamil Nadu, Mumbai and other parts of Maharashtra, Hetero Healthcare said in a statement.

Lupin recalls 5.61 lakh pouches of India-made birth control pills in US

Lupin recalls 5.61 lakh pouches of India-made birth control pills in US

Rediff.com21 Aug 2020

Baltimore-based Lupin Pharmaceuticals Inc is recalling 5,60,922 pouches of Mibelas 24 Fe (norethindrone acetate and Ethinyl estradiol tablets and ferrous fumarate tablets) in the US, as per the latest enforcement report by the USFDA.

DCGI approves mRNA Covid jab for 18 yrs & above; Covovax for 7-11 yrs

DCGI approves mRNA Covid jab for 18 yrs & above; Covovax for 7-11 yrs

Rediff.com28 Jun 2022

The DCGI's nod came after the subject expert committee on COVID-19 of the CSDCO last week recommended granting emergency use authorisation to Covovax for the age group of 7 to 11 years.

Bharat Biotech to produce 700 mn Covaxin doses annually

Bharat Biotech to produce 700 mn Covaxin doses annually

Rediff.com20 Apr 2021

The Hyderabad-based manufacturer uses a proprietary adjuvant Algel-IMDG, which has now proven to be a safe and effective adjuvant, especially to stimulate memory T cell responses.

DCGI approves Covovax for emergency use in 12-17 yrs age group

DCGI approves Covovax for emergency use in 12-17 yrs age group

Rediff.com9 Mar 2022

Confirming the Drugs Controller General Of India (DCGI) approval, Serum Institute of India CEO Adar Poonawalla on Tuesday tweeted: '@SerumInstIndia's brand Covovax has completed bridging studies in India and has been granted Emergency Use Authorisation by DCGI for adults and for children above the age of 12. Younger age groups will follow shortly.'

Charge officers sitting over vaccine production with manslaughter: HC

Charge officers sitting over vaccine production with manslaughter: HC

Rediff.com2 Jun 2021

Officers sitting over untapped potential to make COVID-19 vaccines need to be charged with 'manslaughter' as it is leading to so many deaths, the Delhi high court said on Wednesday, observing that a lot of scope and infrastructure is available in India which is not being used.

How India narrowly escaped a health crisis

How India narrowly escaped a health crisis

Rediff.com5 Dec 2017

The Philippines launches probe after Sanofi reveals WHO-approved dengvaxia - a dengue vaccine - aggravates symptoms in some cases.

GSK withdraws sale of Zinetac after health alert

GSK withdraws sale of Zinetac after health alert

Rediff.com26 Sep 2019

GSK is continuing with investigations into the potential source of the NDMA, which is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables.

Barsu refinery: People must be taken into confidence, says Uddhav

Barsu refinery: People must be taken into confidence, says Uddhav

Rediff.com28 Apr 2023

Thackeray, whose Maha Vikas Aghadi government fell after a rebellion in June last year by his cabinet colleague Eknath Shinde, who went on to become CM, also warned he would extract revenge for his ouster.

Key mantra for India's pharma sector in 2023

Key mantra for India's pharma sector in 2023

Rediff.com21 Dec 2022

Reinvent and innovate will be the key mantra for the Indian pharma industry in the New Year as the 'pharmacy of the world' looks to move from volume to value leadership, amid emerging challenges of inflation and pricing pressures in the global markets. While R&D investment, market competitiveness, regulatory scrutiny, and domestic price regulations are expected to shape the growth of generics and injectable products, concerns such as price control and customs duties on medical equipment will continue to bother the healthcare industry in 2023. The industry believes that in view of India's G20 Presidency, digital health innovation, achieving universal health coverage, improving healthcare infrastructure and delivery will continue to be the key driving factors in 2023.

Every 3rd tablet in the US market is from India

Every 3rd tablet in the US market is from India

Rediff.com9 Jul 2020

India lost its competitive advantage as China gave fiscal benefits to its local manufacturers. Besides, recent policy flip-flops have, however, dented India's image as the 'pharmacy of the world'.

Serum Institute seeks DCGI nod for Covovax

Serum Institute seeks DCGI nod for Covovax

Rediff.com29 Oct 2021

There were no safety concerns arising from the study data and Covovax is safe and immunogenic in the adult population, Prakash Kumar Singh, Director, Government and Regulatory Affairs at the Serum Institute of India (SII), is learnt to have said in the application sent to the DCGI.

DGPs meet warns of 5G network's security vulnerabilities

DGPs meet warns of 5G network's security vulnerabilities

Rediff.com24 Jan 2023

The papers noted that the 5G network is built on easily accessible and open Internet protocols and it inherits all the vulnerabilities of previous generations which make it vulnerable to cyber-attacks and compromising the security of the entire system.

Senators urge Kerry to press India on trade during visit

Senators urge Kerry to press India on trade during visit

Rediff.com15 Jun 2013

Kerry is scheduled to head to India later this month for the fourth annual US-India Strategic Dialogue.

Novovax Covid vaccine likely to get nod in India ahead of US

Novovax Covid vaccine likely to get nod in India ahead of US

Rediff.com18 Aug 2021

Adar Poonawalla said he was hopeful that Covovax, the Novavax vaccine made by SII, will be launched around October this year for adults and for children by the first quarter of next year, depending on DCGI approvals.

'A lot has been done between India and the US in the last two years than it was done before'

'A lot has been done between India and the US in the last two years than it was done before'

Rediff.com23 Jun 2023

'With Trump, the relationship was very transactional, whereas with President Biden it is very structured.'

Bharat Biotech plans to supply 90 million Covaxin doses a month by Dec

Bharat Biotech plans to supply 90 million Covaxin doses a month by Dec

Rediff.com30 Sep 2021

In September, Bharat Biotech aimed to supply 35 million doses, and take this up to 55 million by October. This is still less than what the Indian government expects from the company.

Food safety regulator and industry at loggerheads again

Food safety regulator and industry at loggerheads again

Rediff.com29 Nov 2015

The bone of contention is product approvals, which pharma and neutraceuticals companies say cannot be re-introduced through the regulation route

'Decisive turning point': PM hails approval to vaccines

'Decisive turning point': PM hails approval to vaccines

Rediff.com3 Jan 2021

In a series of tweets after the Drugs Controller General of India (DCGI) approved Oxford's vaccine Covishield and Bharat Biotech's Covaxin for restricted emergency use, Modi said it will make every Indian proud that both the vaccines are made in India.

SRK's son among 8 arrested by NCB during cruise raid, sent to custody

SRK's son among 8 arrested by NCB during cruise raid, sent to custody

Rediff.com4 Oct 2021

Besides Aryan Khan, the arrested accused are identified as Munmun Dhamecha, Arbaaz Merchant, Ismeet Singh, Mohak Jaswal, Gomit Chopra, Nupur Sarika, and Vikrant Chhokar.

What lies ahead for Sun Pharma post Ranbaxy merger approval

What lies ahead for Sun Pharma post Ranbaxy merger approval

Rediff.com31 Mar 2015

Sun Pharmaceutical's acquisition of Ranbaxy has received final approvals.

Cipla to price Remdesivir for Covid-19 under Rs 5,000

Cipla to price Remdesivir for Covid-19 under Rs 5,000

Rediff.com25 Jun 2020

Hetero has priced the injectable drug at Rs 5,400 per 100 mg vial. With More drugmakers in line to launch the drug soon, the prices may see a further erosion.

Enough stockpile of COVID-19 vaccine for priority groups: Niti member

Enough stockpile of COVID-19 vaccine for priority groups: Niti member

Rediff.com4 Jan 2021

Paul noted that "three to four months from now, there will be other vaccines and the stockpile will be even bigger. "And more acceleration can be brought about in the vaccination programme," Paul added.

COVID-19 Vaccine: 4 months from lab to jab

COVID-19 Vaccine: 4 months from lab to jab

Rediff.com8 Jun 2021

'Almost 70 per cent production time of a vaccine is dedicated to quality control, which is done through several hundred tests.'

Biological E's Corbevax cleared as Covid booster dose

Biological E's Corbevax cleared as Covid booster dose

Rediff.com4 Jun 2022

BE's Corbevax is the first such vaccine in India to be approved as a heterologous COVID-19 booster in the country.

Covaxin output scaled up to 500 million jabs a year: Bharat Biotech

Covaxin output scaled up to 500 million jabs a year: Bharat Biotech

Rediff.com17 May 2021

This apart, to further increase capacities, Bharat Biotech has partnered with Indian Immunologicals (IIL) to manufacture the drug substance for Covaxin. The technology transfer process is underway and IIL has the 'capabilities and expertise' to manufacture the inactivated viral vaccines at commercial scale.

Nasal Covid Vaccine Available In Jan

Nasal Covid Vaccine Available In Jan

Rediff.com28 Dec 2022

The vaccine would not have production scalability issues unlike Covaxin, Bharat Biotech's COVID-19 virus vaccine.

Govt places urgent orders for 11.45 cr HCQ tablets

Govt places urgent orders for 11.45 cr HCQ tablets

Rediff.com2 May 2020

A senior official at the health ministry told ANI: "For HCQ, we have placed orders for about 11.45 crore tablets to two Indian firms -- IPCA laboratories and Zydus Cadila. So far, we have received 6.64 crore HCQ drugs and remaining will arrive by May 16."

USFDA denies Covaxin emergency use nod, to take 'full approval' route

USFDA denies Covaxin emergency use nod, to take 'full approval' route

Rediff.com11 Jun 2021

In a setback that could potentially delay the launch of Bharat Biotech's Covid-19 vaccine Covaxin in USA, the Food and Drug Administration there has "recommended" Ocugen Inc, the US partner of the Indian vaccine maker, to go for Biologics Licence Application (BLA) route with additional data, nixing hopes of Emergency Use Authorisation.

New test can predict your level of immunity against COVID-19

New test can predict your level of immunity against COVID-19

Rediff.com10 Aug 2022

Easy access to this kind of test could help people determine what kind of precautions they should take against COVID-19 infection, such as getting an additional booster shot, the researchers said.

Millions of Covid vaccine doses are set to expire in India

Millions of Covid vaccine doses are set to expire in India

Rediff.com20 Jun 2022

Pune-based Serum Institute of India (SII) is sitting on 200 million doses of Covishield that were manufactured in December and are set to expire in September. The company is likely to destroy these vaccines if nothing works out, Sohini Das reports.

'Probe important': Court extends Aryan Khan's NCB custody

'Probe important': Court extends Aryan Khan's NCB custody

Rediff.com4 Oct 2021

The court, in its order, noted that the investigation in the case was of prime importance and considering this aspect, the further presence of the accused before the NCB was necessary.

Declare 'black fungus' as notifiable disease: Centre to states

Declare 'black fungus' as notifiable disease: Centre to states

Rediff.com21 May 2021

As cases of 'black fungus' among COVID-19 patients in the country rise to cross 7,000, the Centre on Thursday urged all states and union territories to declare it as a notifiable disease under the Epidemic Diseases Act to ensure mandatory surveillance to tackle the 'new challenge'.

US lawmakers, businesses demand Indian trade reforms

US lawmakers, businesses demand Indian trade reforms

Rediff.com19 Jun 2013

Next week, US Secretary of State John Kerry travels to India for the fourth annual US-India Strategic Dialogue

Govt fast-tracks approval for foreign-produced COVID vaccines

Govt fast-tracks approval for foreign-produced COVID vaccines

Rediff.com13 Apr 2021

The first 100 beneficiaries of such foreign vaccines shall be assessed for seven days for safety outcomes before it is rolled out for further immunisation programme within the country, the Union health ministry said.

Covaxin shelf life extended, Bharat Biotech relabels old stocks

Covaxin shelf life extended, Bharat Biotech relabels old stocks

Rediff.com5 Jan 2022

The company had in December said that the CDSCO had approved a 12-month shelf life for Covaxin, which was nine months earlier, Sohini Das reports.

Pfizer withdraws emergency use for its Covid vaccine in India

Pfizer withdraws emergency use for its Covid vaccine in India

Rediff.com5 Feb 2021

An expert panel of the country's drugs regulatory authority had recommended against granting such approval to the firm at this stage just two days ago, officials said.

GST meet on June 12 will discuss tax exemption on Covid essentials

GST meet on June 12 will discuss tax exemption on Covid essentials

Rediff.com11 Jun 2021

The Goods and Services Tax (GST) Council, chaired by Union Finance Minister Nirmala Sitharaman, will likely consider on Saturday a GST rate cut for Covid-19 relief essentials and drugs for treating the black fungus disease and might leave the vaccines untouched. The meeting is being held following a report submitted by a Group of Ministers (GoM) to the GST Council on Monday. The GoM, set up by the Council on May 28, was mandated to look at tax exemption and concessions on various Covid items including vaccines, drugs, and equipment.

DCGI finds no link between Covid vaccine shot and 'adverse' reaction

DCGI finds no link between Covid vaccine shot and 'adverse' reaction

Rediff.com2 Dec 2020

The DCGI arrived at the conclusion on Wednesday based on the recommendations of an independent expert committee which has also opined that compensation should not be paid to the volunteer, they said.

Aryan Khan's bail plea to be heard on Oct 13

Aryan Khan's bail plea to be heard on Oct 13

Rediff.com11 Oct 2021

Aryan Khan was arrested on October 3. He is currently in judicial custody and lodged at the Arthur Road prison in Mumbai.